Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
Aims. To evaluate carotid intima-media thickness (cIMT) and biomarkers of the osteoprotegerin/receptor activator of nuclear factor-κB ligand (OPG/RANKL) system in type 1 diabetes (T1DM) children and adolescents and controls. Subjects and Methods. Fifty six T1DM patients (mean ± SD age: 12.0 ± 2.7 ye...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2013/102120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563658871275520 |
|---|---|
| author | Irene Lambrinoudaki Emmanouil Tsouvalas Marina Vakaki George Kaparos Kimon Stamatelopoulos Areti Augoulea Paraskevi Pliatsika Andreas Alexandrou Maria Creatsa Kyriaki Karavanaki |
| author_facet | Irene Lambrinoudaki Emmanouil Tsouvalas Marina Vakaki George Kaparos Kimon Stamatelopoulos Areti Augoulea Paraskevi Pliatsika Andreas Alexandrou Maria Creatsa Kyriaki Karavanaki |
| author_sort | Irene Lambrinoudaki |
| collection | DOAJ |
| description | Aims. To evaluate carotid intima-media thickness (cIMT) and biomarkers of the osteoprotegerin/receptor activator of nuclear factor-κB ligand (OPG/RANKL) system in type 1 diabetes (T1DM) children and adolescents and controls. Subjects and Methods. Fifty six T1DM patients (mean ± SD age: 12.0 ± 2.7 years, diabetes duration: 5.42 ± 2.87 years and HbA1c: 8.0 ± 1.5%) and 28 healthy matched controls, were studied with anthropometric and laboratory measurements, including serum OPG, soluble RANKL (sRANKL) and cIMT. Results. Anthropometric, laboratory, and cIMT measurements were similar between T1DM youngsters and controls. However patients with longer diabetes duration (>/7.0 years) had indicatively higher cIMT (cIMT = 0.49 vs 0.44 mm, P 0.072) and triglyceride levels than the rest of the patients (93.7 vs 64.6 mg/dl, P 0.025). Both in the total study population (β 0.418, P 0.027) and among T1DM patients separately (β 0.604, P 0.013), BMI was the only factor associated with cIMT. BMI was further associated with OPG in both groups (β −0.335, P 0.003 and β −0.356, P 0.008 respectively), while sRANKL levels were not associated with any factor. Conclusions. BMI was the strongest independent predictor of cIMT among the whole population, and especially in diabetics, suggesting a possible synergistic effect of diabetes and adiposity on atherosclerotic burden. BMI was overall strongly associated with circulating OPG, but the causes of this association remain unclear. |
| format | Article |
| id | doaj-art-bb7ee788d45245609189380289a796c5 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-bb7ee788d45245609189380289a796c52025-02-03T01:12:59ZengWileyInternational Journal of Endocrinology1687-83371687-83452013-01-01201310.1155/2013/102120102120Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes MellitusIrene Lambrinoudaki0Emmanouil Tsouvalas1Marina Vakaki2George Kaparos3Kimon Stamatelopoulos4Areti Augoulea5Paraskevi Pliatsika6Andreas Alexandrou7Maria Creatsa8Kyriaki Karavanaki92nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece2nd Department of Pediatrics, Diabetes & Metabolism Clinic, University of Athens, “P&A Kyriakou” Children's Hospital, Athens, GreeceRadiology Department, “P&A Kyriakou” Children's Hospital, Athens, GreeceHormonal Laboratory, University of Athens, Aretaieio Hospital, Athens, GreeceDepartment of Therapeutics, University of Athens, Alexandra Hospital, Athens, Greece2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece2nd Department of Pediatrics, Diabetes & Metabolism Clinic, University of Athens, “P&A Kyriakou” Children's Hospital, Athens, GreeceAims. To evaluate carotid intima-media thickness (cIMT) and biomarkers of the osteoprotegerin/receptor activator of nuclear factor-κB ligand (OPG/RANKL) system in type 1 diabetes (T1DM) children and adolescents and controls. Subjects and Methods. Fifty six T1DM patients (mean ± SD age: 12.0 ± 2.7 years, diabetes duration: 5.42 ± 2.87 years and HbA1c: 8.0 ± 1.5%) and 28 healthy matched controls, were studied with anthropometric and laboratory measurements, including serum OPG, soluble RANKL (sRANKL) and cIMT. Results. Anthropometric, laboratory, and cIMT measurements were similar between T1DM youngsters and controls. However patients with longer diabetes duration (>/7.0 years) had indicatively higher cIMT (cIMT = 0.49 vs 0.44 mm, P 0.072) and triglyceride levels than the rest of the patients (93.7 vs 64.6 mg/dl, P 0.025). Both in the total study population (β 0.418, P 0.027) and among T1DM patients separately (β 0.604, P 0.013), BMI was the only factor associated with cIMT. BMI was further associated with OPG in both groups (β −0.335, P 0.003 and β −0.356, P 0.008 respectively), while sRANKL levels were not associated with any factor. Conclusions. BMI was the strongest independent predictor of cIMT among the whole population, and especially in diabetics, suggesting a possible synergistic effect of diabetes and adiposity on atherosclerotic burden. BMI was overall strongly associated with circulating OPG, but the causes of this association remain unclear.http://dx.doi.org/10.1155/2013/102120 |
| spellingShingle | Irene Lambrinoudaki Emmanouil Tsouvalas Marina Vakaki George Kaparos Kimon Stamatelopoulos Areti Augoulea Paraskevi Pliatsika Andreas Alexandrou Maria Creatsa Kyriaki Karavanaki Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus International Journal of Endocrinology |
| title | Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus |
| title_full | Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus |
| title_fullStr | Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus |
| title_full_unstemmed | Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus |
| title_short | Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus |
| title_sort | osteoprotegerin soluble receptor activator of nuclear factor κb ligand and subclinical atherosclerosis in children and adolescents with type 1 diabetes mellitus |
| url | http://dx.doi.org/10.1155/2013/102120 |
| work_keys_str_mv | AT irenelambrinoudaki osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT emmanouiltsouvalas osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT marinavakaki osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT georgekaparos osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT kimonstamatelopoulos osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT aretiaugoulea osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT paraskevipliatsika osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT andreasalexandrou osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT mariacreatsa osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus AT kyriakikaravanaki osteoprotegerinsolublereceptoractivatorofnuclearfactorkbligandandsubclinicalatherosclerosisinchildrenandadolescentswithtype1diabetesmellitus |